Tepha in $10.7m financing:
This article was originally published in Clinica
Executive Summary
Tepha, a developer of absorbable devices for therapeutic applications, has closed a $10.7m venture capital financing in a bid to support the development of its TephaFLEX biopolymer technology platform, which it licensed from Metabolix. The funding was led by the Vertical Group, and backed by Integra Ventures, Novartis Venture Fund and Westfield Life Sciences Fund. Cambridge, Massachusetts-based Tepha is currently working with several companies to incorporate the TephaFLEX into the development of other devices, such as surgical meshes, haemostats, intra-cardiac devices, absorbable stents, ligament and tendon repair devices and drug delivery systems. The firm has received US marketing clearances for its TephaFLEX absorbable and surgical mesh.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.